Key Takeaways Retatrutide (LY3437943) is an investigational weight loss medication developed by Eli Lilly Triple-agonist mechanism: First drug to activate GLP-1, GIP, and glucagon receptors simultaneously Phase 2 results: Up to 24.2% weight loss at 48 weeks (approximately 58 lbs for a 240-lb person) Not FDA-approved: Currently in Phase 3 clinical trials, expected approval in 20272028 How it differs: Outperforms semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in weight loss trials Access now: Clinical trials (free), compounding pharmacies, or research peptide vendors What Is Retatrutide
So if you normally inject on Tuesday and want to move to Friday, you would inject on your regular Tuesday, then wait until at least Friday of the same week for your next dose, then continue on Fridays going forward
L-carnitine is synthesized in the brain, liver, and kidneys from the amino acids methionine and lysine and is critical to heart and brain function, muscle movement, and several other body processes
For patients who are needle-averse or highly cost-sensitive, Qsymia may come up as an option, but for most patients Wegovy offers a more meaningful and well-rounded treatment
